Presenilin, Notch, and the genesis and treatment of Alzheimer's disease
- PMID: 11572965
- PMCID: PMC58679
- DOI: 10.1073/pnas.211352598
Presenilin, Notch, and the genesis and treatment of Alzheimer's disease
Abstract
Elucidation of the proteolytic processing of the amyloid beta-protein precursor (APP) has revealed that one of the two proteases (gamma-secretase) that cleave APP to release amyloid beta-protein (Abeta) is likely to be presenilin. Presenilin also mediates the gamma-secretase-like cleavage of Notch receptors to enable signaling by their cytoplasmic domains. Therefore, APP and Notch may be the first identified substrates of a unique intramembranous aspartyl protease that has presenilin as its active-site component. In view of the evidence for a central role of cerebral build-up of Abeta in the pathogenesis of Alzheimer's disease, this disorder appears to have arisen in the human population as a late-life consequence of the conservation of a critical developmental pathway.
References
-
- Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, et al. Nat Med. 1997;3:67–72. - PubMed
-
- Esler W P, Kimberly W T, Ostaszewski B L, Diehl T s, Moore C L, Tsai J-Y, Rahmati T, Xia W, Selkoe D J, Wolfe M S. Nat Cell Biol. 2000;2:428–434. - PubMed
-
- Kimberly W T, Xia W, Rahmati R, Wolfe M S, Selkoe D J. J Biol Chem. 2000;275:3173–3178. - PubMed
-
- Wolfe M S, Xia W, Ostaszewski B L, Diehl T S, Kimberly W T, Selkoe D J. Nature (London) 1999;398:513–517. - PubMed
-
- Wolfe M S, Xia W, Moore C L, Leatherwood D D, Ostaszewski B L, Rahmati T, Donkor I O, Selkoe D J. Biochemistry. 1999;38:4720–4727. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
